CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Hanmi Pharmaceutical Signs Fabry Disease Drug Licensing Deal With BioMarin Worth Up to USD 237.5 Million

By Public Technologies
  • Hanmi Pharmaceutical signed a USD 237.5 million licensing agreement with BioMarin Pharmaceutical for Fabry disease treatment LA-GLA on Oct. 29, 2026.
  • Terms include USD 35 million upfront, USD 202.5 million in milestone payments and royalties on annual net sales.
  • BioMarin receives exclusive global rights to research, develop, manufacture and commercialize the treatment through the royalty period.
  • South Korean approval and commercialization rights remain with Hanmi and Green Cross.
  • The treatment, jointly developed with Green Cross, is undergoing Phase 1/2 clinical trials in South Korea and abroad.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanmi Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030800002), on October 30, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk